GlassScriptPhysician profile
Andrea Mernitz
NPI 1962460964
$5,784.87
in general payments reported to CMS, 2019-2025
46 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $321 · 2021: $214 · 2022: $638 · 2023: $1,096 · 2024: $1,812 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,949 · Education: $72.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,949.05 |
| Education | $72.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $721.82 | 2021-2025 | |
| Lilly USA, LLC | $709.51 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $686.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Supernus Pharmaceuticals, INC. | $406.22 | 2022-2025 | Qelbree, Qelbree |
| Pfizer INC. | $299.71 | 2019-2025 | |
| Glaxosmithkline, LLC. | $289.78 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.11 | 2019-2025 | Jardiance, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $224.91 | 2020-2024 | Farxiga, Bevespi Aerosphere |
| Amgen INC. | $178.54 | 2019-2025 | Otezla, Repatha, Otezla |
| Astellas Pharma US INC | $160.30 | 2019-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $159.66 | 2022-2025 | Rexulti |
| Corium, LLC | $151.08 | 2024-2025 | Azstarys |
| Novartis Pharmaceuticals Corporation | $146.48 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $138.48 | 2019-2025 | Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $132.51 | 2021-2025 | Trintellix |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Mernitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.